Skip to main content

What the FDA labels say about taking them together

Obinutuzumab and rasburicase

Obinutuzumab's FDA label of December 19, 2025 names rasburicase in its warnings and precautions section; the rasburicase label PlainMeds reads does not name obinutuzumab. The obinutuzumab label: “In patients with CLL and NHL at risk for TLS, administer appropriate tumor lysis prophylaxis with anti-hyperuricemics and hydration prior to the infusion of GAZYVA.”

Check it at the source: the obinutuzumab FDA label on DailyMed (effective December 19, 2025, Genentech, Inc.); the rasburicase FDA label on DailyMed (effective July 30, 2026, Sanofi-Aventis U.S. LLC).

What does the obinutuzumab label say about rasburicase?

Obinutuzumab label, warnings and precautions

In patients with CLL and NHL at risk for TLS, administer appropriate tumor lysis prophylaxis with anti-hyperuricemics (e.g., allopurinol or rasburicase) and hydration prior to the infusion of GAZYVA [see Dosage and Administration (2.4) ].

Source: FDA drug label (Gazyva), Genentech, Inc., effective December 19, 2025 (SPL set df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda), via openFDA; the full label on DailyMed

What does the rasburicase label say about obinutuzumab?

Rasburicase's label (effective July 30, 2026) does not name obinutuzumab in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Elitek), Sanofi-Aventis U.S. LLC, effective July 30, 2026 (SPL set 0ae10bc4-6b65-402f-9db5-2d7753054922), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Obinutuzumab generic labelers
0Rasburicase generic labelers
ObinutuzumabRasburicase
Labeled forLeukemia, lymphoma and myeloman/a
Boxed warningYesYes
Pharmacy cost (NADAC)n/an/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?